SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that its global launch of its SQiDliteMultiplexingSystem will take place at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place in Chicago IL, October 14-18. SQiDlite was developed to address the multiplex testing needs of clinical diagnostic laboratories, pharmaceutical drug development and Contract Research Organizations (CRO) performing bioanalytical and immunogenicity testing.
SQI Diagnostics has successfully cleared multiplex diagnostic assays to run on its other fully automated system, SQiDworks, a high-throughput microarray platform that can perform qualitative or quantitative testing for multiple biomarkers simultaneously.
The SQiDlite System offers laboratories of all sizes flexible, configurable, fully automated workflow solutions from dilutions through reporting to run protein and antibody multiplexed immunoassays. The SQiDlite integrates fluidics, washer, dryer, scanner and analyzing functions in a user-friendly bench-top footprint.
â€śWe believe that the SQiDlite System is the perfect complement to our custom assay business in that it is a completely automated, small footprint bench-top platform with total load-and-go capabilitiesâ€ť said Claude Ricks, CEO of SQI Diagnostics. â€śWith its user-friendly assay development software and LIS interface combined with its ability to significantly reduce cost and labour, SQiDlite is positioned to become a platform of choice for bioanalytics and immunogenicity labs around the world.â€ť
SQI Diagnostics is an exhibitor at this yearâ€™s AAPS Annual Meeting in Chicago, IL. SQI science and commercial teams will be demonstrating the advanced functionality of this bench-top system and its software functionalities created to speed assay development in booth #1244.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Companyâ€™s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.
For more information about SQiDlite and SQI Diagnosticsâ€™ suite of biopharma and clinical diagnostics products and services please visit www.sqidiagnostics.com, or contact SQI at: firstname.lastname@example.org
This press release contains certain forward-looking statements, including, without limitation, statements containing the words â€śmayâ€ť, â€śplanâ€ť, â€świllâ€ť, â€śestimateâ€ť, â€ścontinueâ€ť, â€śanticipateâ€ť, â€śintendâ€ť, â€śexpectâ€ť, â€śbelieveâ€ť, â€śin the processâ€ť, â€śis subject toâ€ť and other similar expressions which constitute â€śforward-looking informationâ€ť within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Companyâ€™s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Business Wire
Last updated on: 12/10/2012